Table 1

Ongoing clinical trials with unengineered iPSC-derived NK cells

Trial identifierIntervention(s)PhaseCancer subtypesDate initiated
  1. iPSC-NK monotherapy

  2. iPSC-NK with nivolumab, pembrolizumab, or atezolizumab

  3. iPSC-NK with IL-2 and nivolumab, pembrolizumab, or atezolizumab

IVarious advanced solid tumorsFebruary 2019
NCT04023071High-affinity, non-cleavable CD16 iPSC-NK with or without rituximab or obinutuzumabIAML (monotherapy) or B-cell lymphoma (combination)July 2019
NCT04630769High-affinity, non-cleavable CD16 iPSC-NK at various doses with or without enoblituzumabIOvarian, fallopian tube, or primary peritoneal cancerNovember 2020
  • AML, acute myeloid leukemia; iPSC, induced pluripotent stem cell; NK, natural killer.